Payment overview · 2025
General Payments
$587.99
10 reported records · 6 companies
Healthcare provider profile · identity verified
Yiding Li, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BROOKLYN, NY · NPI 1295939494
Verified facts
What the public records show
CMS Open Payments records show Yiding Li, M.D. received $587.99 in general payments during 2025 across 10 reported records.
PFIZER INC. accounted for 27.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Prolia, Shingrix.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Shingrix by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Abrysvo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $162.12 | 27.6% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $125.00 | 21.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $125.00 | 21.3% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$98.15 | 16.7% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $40.22 | 6.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $37.50 | 6.4% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $587.99 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $162.12 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| CLOSUREFAST Normalized: closurefast |
Device | Medtronic, Inc. | $98.15 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $45.95 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $45.95 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $40.22 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $19.59 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $17.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 85 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 53 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 16 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
53 | 33 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
16 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
85 | 83 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 533 | 131 |
| Vascepa | Icosapent Ethyl | 391 | 76 |
| Amlodipine Besylate | Amlodipine Besylate | 361 | 77 |
| Alendronate Sodium | Alendronate Sodium | 314 | 77 |
| Losartan Potassium | Losartan Potassium | 282 | 67 |
| Jardiance | Empagliflozin | 266 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 250 | 54 |
| Diclofenac Epolamine | Diclofenac Epolamine | 199 | 40 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 186 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 185 | 60 |
| Metformin Hcl | Metformin Hcl | 183 | 46 |
| Omeprazole | Omeprazole | 172 | 63 |
| Diclofenac Sodium | Diclofenac Sodium | 155 | 51 |
| Simvastatin | Simvastatin | 151 | 35 |
| Ammonium Lactate | Ammonium Lactate | 139 | 52 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 129 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 125 | 31 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 124 | 28 |
| Januvia | Sitagliptin Phosphate | 114 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 109 | 34 |
| Linzess | Linaclotide | 105 | 26 |
| Montelukast Sodium | Montelukast Sodium | 95 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 93 | 33 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 93 | 35 |
| Glipizide Er | Glipizide | 93 | 25 |
| Trazodone Hcl | Trazodone Hcl | 91 | 39 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 88 | 26 |
| Ibuprofen | Ibuprofen | 87 | 64 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 85 | 83 |
| Levothyroxine Sodium | Levothyroxine Sodium | 81 | 19 |
| Nebivolol Hcl | Nebivolol Hcl | 76 | 16 |
| Metformin Hcl Er | Metformin Hcl | 74 | 20 |
| Azelastine Hcl | Azelastine Hcl | 70 | 23 |
| Allopurinol | Allopurinol | 67 | 17 |
| Donepezil Hcl | Donepezil Hcl | 67 | 13 |
| Xarelto | Rivaroxaban | 65 | 19 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 64 | 17 |
| Meclizine Hcl | Meclizine Hcl | 64 | 41 |
| Icosapent Ethyl | Icosapent Ethyl | 61 | 17 |
| Gabapentin | Gabapentin | 60 | 16 |
| Lisinopril | Lisinopril | 60 | 16 |
| Famotidine | Famotidine | 55 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 13 |
| Hydrocortisone | Hydrocortisone | 54 | 37 |
| Promethazine Hcl | Promethazine Hcl | 54 | 39 |
| Prolia | Denosumab | 53 | 33 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 51 | suppressed |
| Sucralfate | Sucralfate | 49 | 18 |
| Rybelsus | Semaglutide | 44 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 43 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 40 | 29 |
| Azithromycin | Azithromycin | 34 | 32 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Amoxicillin | Amoxicillin | 33 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 30 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 30 | suppressed |
| Celecoxib | Celecoxib | 29 | 11 |
| Ketoconazole | Ketoconazole | 29 | suppressed |
| Finasteride | Finasteride | 28 | suppressed |
| Mupirocin | Mupirocin | 28 | 24 |
| Valsartan | Valsartan | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 20 |
| Fluocinonide | Fluocinonide | 26 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 24 | suppressed |
| Restasis | Cyclosporine | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 13 |
| Nyamyc | Nystatin | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 13 |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 19 | 15 |
| Telmisartan | Telmisartan | 19 | suppressed |
| Furosemide | Furosemide | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 18 | suppressed |
| Meloxicam | Meloxicam | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 12 |
| Tramadol Hcl | Tramadol Hcl | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Tacrolimus | Tacrolimus | 17 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 16 | 13 |
| Olanzapine | Olanzapine | 16 | 15 |
| Prednisone | Prednisone | 16 | 12 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 16 | 13 |
| Ciclopirox | Ciclopirox | 15 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 15 | suppressed |
| Naproxen | Naproxen | 15 | 13 |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | 13 |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Procto-Med Hc | Hydrocortisone | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $587.99 · 10 records | PFIZER INC. | ABRYSVO, AIRSUPRA, CLOSUREFAST, COMIRNATY, EVENITY, PREVNAR 20, PROLIA, REPATHA, SHINGRIX, ZORYVE | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error